Ponatinib
About
Therapy type: Targeted therapy
Therapy strategy: BCR-ABL inhibition
Mappings
NCI Thesaurus: Ponatinib (coding:ncit:C95777)
RxNorm: ponatinib (coding:rxcui:1364347, coding:omop:43013182)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) FDA (2) | BCR::ABL1 | Acute Lymphoblastic Leukemia | Cytarabine, Dexamethasone, Methotrexate, Ponatinib, Prednisone, Vincristine | |
| FDA (2) | ABL1 p.T315I, BCR::ABL1 | Acute Lymphoblastic Leukemia | Ponatinib | |
| EMA (2) FDA (2) | ABL1 p.T315I, BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Ponatinib | |
| EMA (1) | not BCR::ABL1 | Acute Lymphoblastic Leukemia | Ponatinib | |
| EMA (1) | ABL1 p.T315I, not BCR::ABL1 | Acute Lymphoblastic Leukemia | Ponatinib |